ADVISORY, Aug. 10, 2017 --
What:
Citius Pharmaceuticals, Inc. (Nasdaq:CTXR), a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, will visit the Nasdaq MarketSite in Times Square.
In honor of the occasion, Leonard Mazur, Chairman, will ring the Opening Bell.
Where:
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
When:
Friday, August 11, 2017 – 9:15 a.m. to 9:30 a.m. ET
Citius Pharmaceuticals, Inc. Media Contact:
Andrew Scott
908-967-6677 ext 105
[email protected]
Nasdaq MarketSite Media Contact:
Emily Pan
(646) 441-5120
[email protected]
Feed Information:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK
Social Media:
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
http://www.facebook.com/NASDAQ.
For photos from ceremonies and events, please visit our Instagram page:
http://instagram.com/nasdaq
For livestream of ceremonies and events, please visit our YouTube page:
http://www.youtube.com/nasdaq/live
For news tweets, please visit our Twitter page:
http://twitter.com/nasdaq
For exciting viral content and ceremony photos, please visit our Tumblr page:
http://nasdaq.tumblr.com/
Webcast:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
Photos:
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches. www.citiuspharma.com
About Nasdaq
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com
-NDAQA-


Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Instagram Outage Disrupts Thousands of U.S. Users
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs 



